沃华医药(002107) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥187,421,564.78, representing a 1.18% increase compared to ¥185,240,304.65 in the same period last year[8] - Net profit attributable to shareholders decreased by 21.44% to ¥13,535,130.58 from ¥17,229,854.39 year-on-year[8] - The net profit after deducting non-recurring gains and losses fell by 28.75% to ¥12,181,248.91 compared to ¥17,097,435.02 in the previous year[8] - Basic and diluted earnings per share decreased by 20.00% to ¥0.04 from ¥0.05 in the same period last year[8] - The company reported a decrease in net profit of 41.75% to ¥1,201.77 million, primarily due to reduced profits from its subsidiary[16] - Net profit for Q1 2019 was CNY 12,017,701.91, a decrease of 41.9% from CNY 20,631,220.53 in Q1 2018[37] - The total comprehensive income for the quarter was CNY 15,780,623.31, compared to CNY 13,590,186.64 in the same quarter last year, indicating a growth of 16.0%[42] Cash Flow and Liquidity - The net cash flow from operating activities increased by 42.97% to ¥22,441,407.44 from ¥15,696,505.27 year-on-year[8] - The cash flow from operating activities was not detailed in the provided documents, indicating a need for further analysis on liquidity[35] - The cash outflow from operating activities totaled CNY 216,598,262.32, down from CNY 223,851,295.31 in the previous year[45] - The net cash flow from financing activities amounted to 2,106.80 million[50] - The net increase in cash and cash equivalents for the period was 21,721,979.79 million, compared to 31,882,780.43 million in the previous period[50] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥929,338,635.66, a 0.75% increase from ¥922,375,081.54 at the end of the previous year[8] - The company's current assets totaled CNY 567,957,331.65, slightly up from CNY 561,586,698.77 at the end of 2018[27] - Total liabilities decreased to CNY 221,543,642.01 from CNY 226,597,789.79, a reduction of about 2.2%[28] - The company's equity attributable to shareholders increased to CNY 607,580,773.39 from CNY 594,045,642.81, reflecting a growth of approximately 2.3%[29] - The company's total assets reached CNY 778,552,174.89, up from CNY 768,651,298.70 at the end of the previous period[34] - Total liabilities decreased to CNY 189,898,729.36 from CNY 195,778,476.48, indicating a reduction of 3.5%[33] Research and Development - Research and development expenses for the period were ¥969.30 million, a significant increase of 230.54% compared to the previous year[15] - R&D expenses increased significantly to CNY 9,693,043.38, compared to CNY 2,932,487.34 in the previous year, reflecting a growth of 230.5%[35] Shareholder Activities - The company did not engage in any repurchase transactions among its top shareholders during the reporting period[12] - The company reported no violations regarding external guarantees during the reporting period[20] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[20] - The company did not engage in any research, communication, or interview activities during the reporting period[21] Other Financial Metrics - Total operating costs for Q1 2019 were CNY 175,087,776.95, up 8.5% from CNY 161,344,326.88 year-over-year[35] - Cash and cash equivalents increased to CNY 339,242,050.07 from CNY 322,919,227.83, reflecting a growth of approximately 5.5%[26] - Accounts receivable decreased to CNY 103,591,093.09 from CNY 120,940,312.15, a decline of about 14.4%[26] - Inventory rose to CNY 96,064,623.96, compared to CNY 83,873,279.88, indicating an increase of approximately 14.5%[26] - The company reported a significant increase in prepayments to CNY 2,419,490.93, compared to CNY 1,778,382.44 in the previous year, reflecting a growth of 36.2%[33] - The ending balance of cash and cash equivalents was 273,933,178.41 million, up from 244,036,209.33 million at the beginning of the period[50] - The financial report for the first quarter was not audited[51]